Literature DB >> 14583613

Hepatic erythropoietin gene regulation by GATA-4.

Christof Dame1, Martha C Sola, Kim-Chew Lim, Kelly M Leach, Joachim Fandrey, Yaluan Ma, Gisela Knöpfle, James Douglas Engel, Jörg Bungert.   

Abstract

Erythropoietin production switches from fetal liver to adult kidney during development. GATA transcription factors 2 and 3 could be involved in modulating this switch, because they were shown to negatively regulate erythropoietin gene transcription through a promoter proximal GATA site. Herein, we analyzed the role of several GATA factors in the regulation of the erythropoietin gene in human liver and in hepatoma cells. Although GATA-3 expression in hepatocytes increases during human development, erythropoietin mRNA accumulation is unaltered in mutant mice lacking GATA-3. We found that GATA-2, -3, -4, and -6 are all expressed in human hepatocytes and that GATA-4 exhibits the most prominent Epo promoter binding activity in vitro and in vivo. Inhibition of GATA-4 expression by RNA interference leads to a dramatic reduction in Epo gene transcription in Hep3B cells. Moreover, GATA-4 expression is high and limited to hepatocytes in the fetal liver, whereas GATA-4 expression in the adult liver is low and restricted to epithelial cells surrounding the biliary ducts. Thus, GATA-4 is critical for transcription of the Epo gene in hepatocytes and may contribute to the switch in the site of Epo gene expression from the fetal liver to the adult kidney.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583613     DOI: 10.1074/jbc.M310404200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

Authors:  Ahmed Mohyeldin; Huasheng Lu; Clifton Dalgard; Stephen Y Lai; Noam Cohen; Geza Acs; Ajay Verma
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

Review 2.  GATA switches as developmental drivers.

Authors:  Emery H Bresnick; Hsiang-Ying Lee; Tohru Fujiwara; Kirby D Johnson; Sunduz Keles
Journal:  J Biol Chem       Date:  2010-07-29       Impact factor: 5.157

3.  Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia.

Authors:  Pinelopi P Kapitsinou; Qingdu Liu; Travis L Unger; Jennifer Rha; Olena Davidoff; Brian Keith; Jonathan A Epstein; Sheri L Moores; Connie L Erickson-Miller; Volker H Haase
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

Review 4.  Regulation of erythropoiesis by hypoxia-inducible factors.

Authors:  Volker H Haase
Journal:  Blood Rev       Date:  2013-01-03       Impact factor: 8.250

Review 5.  Hypoxic regulation of erythropoiesis and iron metabolism.

Authors:  Volker H Haase
Journal:  Am J Physiol Renal Physiol       Date:  2010-05-05

Review 6.  Erythropoietin in stroke therapy: friend or foe.

Authors:  Rhonda Souvenir; Desislava Doycheva; John H Zhang; Jiping Tang
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

7.  Specific contribution of the erythropoietin gene 3' enhancer to hepatic erythropoiesis after late embryonic stages.

Authors:  Norio Suzuki; Naoshi Obara; Xiaoqing Pan; Miho Watanabe; Kou-Ichi Jishage; Naoko Minegishi; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2011-07-11       Impact factor: 4.272

Review 8.  Erythropoietin.

Authors:  H Franklin Bunn
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

9.  Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB.

Authors:  Nadine Rohwer; Christof Dame; Anja Haugstetter; Bertram Wiedenmann; Katharina Detjen; Clemens A Schmitt; Thorsten Cramer
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

Review 10.  Survival and proliferative roles of erythropoietin beyond the erythroid lineage.

Authors:  Constance Tom Noguchi; Li Wang; Heather M Rogers; Ruifeng Teng; Yi Jia
Journal:  Expert Rev Mol Med       Date:  2008-12-01       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.